Robert B Laprairie Selected Research

3- (2- nitro- 1- phenylethyl)- 2- phenyl- 1H- indole

1/2021	Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801 on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task.
1/2020	Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert B Laprairie Research Topics

Disease

8	Huntington Disease (Huntington's Disease) 01/2022 - 09/2013
5	Epilepsy (Aura) 01/2023 - 01/2020
5	Pain (Aches) 01/2022 - 01/2017
4	Inflammation (Inflammations) 01/2022 - 10/2016
3	Substance-Related Disorders (Drug Abuse) 01/2023 - 10/2016
3	Absence Epilepsy (Childhood Absence Epilepsy) 06/2022 - 01/2021
3	Glaucoma 01/2022 - 01/2021
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2023 - 01/2021
2	Seizures (Absence Seizure) 01/2023 - 01/2021
2	Schizophrenia (Dementia Praecox) 04/2021 - 01/2021
2	Obesity 11/2019 - 10/2016
1	Gestational Weight Gain 11/2023
1	Nervous System Diseases (Neurological Disorders) 11/2023
1	Anhedonia 02/2023
1	Mood Disorders (Mood Disorder) 01/2023
1	Mental Disorders (Mental Disorder) 01/2023
1	Neuroblastoma 05/2022
1	Neoplasms (Cancer) 05/2022
1	Neuralgia (Stump Neuralgia) 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Immune System Diseases (Immune Disorders) 01/2022
1	Catalepsy 01/2021
1	Psychotic Disorders (Schizoaffective Disorder) 01/2021
1	Drug Resistant Epilepsy 01/2020
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020
1	Hypothermia 01/2019
1	Chorea (Rheumatic Chorea) 01/2018

Drug/Important Bio-Agent (IBA)

13	Cannabinoid Receptors (Cannabinoid Receptor)IBA 02/2023 - 09/2013
11	CannabinoidsIBA 01/2023 - 09/2013
8	EndocannabinoidsIBA 01/2021 - 02/2014
3	GTP-Binding Proteins (G-Protein)IBA 01/2022 - 01/2017
2	OrexinsIBA 01/2023 - 01/2021
2	LigandsIBA 01/2022 - 01/2018
2	2-phenylindoleIBA 01/2022 - 11/2021
2	CannabidiolIBA 01/2021 - 01/2020
2	3- (2- nitro- 1- phenylethyl)- 2- phenyl- 1H- indoleIBA 01/2021 - 01/2020
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 01/2020
1	SmokeIBA 11/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	Orexin ReceptorsIBA 02/2023
1	YNT-185IBA 02/2023
1	RimonabantIBA 02/2023
1	Lysergic Acid Diethylamide (LSD)IBA 01/2023
1	T-Type Calcium Channels (T-Type Calcium Channel)IBA 01/2023
1	Psilocybin (Psilocibin)IBA 01/2023
1	psilocinIBA 01/2023
1	Hallucinogens (Psychedelics)IBA 01/2023
1	CB2 Cannabinoid ReceptorIBA 05/2022
1	Antipsychotic Agents (Antipsychotics)IBA 04/2021
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 04/2021
1	Dizocilpine Maleate (Dizocilpine)IBA 01/2021
1	Glutamic Acid (Glutamate)FDA Link 01/2021
1	3- (2- hydroxy- 4- (1,1- dimethylheptyl)phenyl)- 4- (3- hydroxypropyl)cyclohexanolIBA 01/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2020
1	Opioid Analgesics (Opioids)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 01/2020
1	EnzymesIBA 01/2020
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2019
1	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2018
1	amsonic acid (DAS)IBA 02/2015
1	Dopamine (Intropin)FDA LinkGeneric 02/2015
1	CytokinesIBA 02/2014
1	Huntingtin ProteinIBA 09/2013

Therapy/Procedure

4	Therapeutics 01/2023 - 01/2020
1	Pain Management 10/2016